Report Overview

The global chikungunya Diagnostics & Treatment  market is estimated to have reached USD 1.20 billion in 2020 and is further projected to reach USD 1.98 billion by 2027, growing at a CAGR of 7.4% during 2021-2027

Global Chikungunya Diagnostics & Treatment  Market Size- Industry Trends & Forecast Report 2027.

The global chikungunya Diagnostics & Treatment  market is estimated to have reached USD 1.20 billion in 2020 and is further projected to reach USD 1.98 billion by 2027, growing at a CAGR of 7.4% during 2021-2027 (forecast period). The Chikungunya Diagnostics & Treatment  market is likely to grow in the forecast timeframe due to the rising incidence of chikungunya worldwide, increasing awareness about mosquito-transmitted infections, and government initiatives regarding the prevention and control of mosquito infestation and the disease. The factors driving the market for chikungunya diagnosis are government efforts regarding the prevention of mosquito breeding and rising general awareness among people about mosquito bites and the resulting infections.

 

Source: BlueWeave Consulting

 

Global Chikungunya Fever Market Overview:

Chikungunya (chik-un-GUN-yuh) is known as a viral illness transmitted by mosquitoes that cause the sudden onset of fever and severe joint pain. The signs and symptoms may include fatigue, muscle pain, headache, and rash. The outbreak of the Chikungunya was first reported in Africa, Asia, Europe, and islands in the Indian and Pacific oceans. The first reported case of chikungunya in the Americas occurred in 2013, on islands in the Caribbean. Since then, more than 1.7 million suspected cases of chikungunya have been reported in the Caribbean islands, Latin American countries, and the United States. Canada and Mexico also have reported cases of infection.

 

Chikungunya Diagnostics & Treatment  Market Forecast and Trends

 

Growth Drivers 

 

Expanding R&D expenses for the treatment of chikungunya is driving the market 

The rapidly increasing research on Chikungunya is acting as a major driver for the market. For instance, scientists have identified a molecule found on human cells and some animal cells that could be a useful target for drugs against chikungunya virus infection and related diseases, according to new research published in the journal Nature. Chikungunya, an alphavirus, is particularly transmitted to humans by the bite of an infected mosquito. And currently growing research on specific treatment to cure the chikungunya virus and prevention of fever and debilitating joint pain and arthritis is driving the market. Small, sporadic outbreaks of chikungunya occurred in Africa, Asia, Europe, and the Indian and Pacific Oceans after the virus was identified in the 1950s. In 2013, the virus spread to the Americas and has since caused a widespread and ongoing epidemic. The scientists have particularly aimed to better understand which traits make humans susceptible to chikungunya virus infection. 

 

Rising awareness among the people about Chikungunya Diagnostics & Treatment  is acting as a driver for the market

Chikungunya is a viral disease spread by mosquitoes that causes fever and severe joint pains. It is spread to humans by the bite of an infected mosquito, and hence many health centers are putting their best efforts to make people aware of this fever. For instance, a chikungunya outbreak was identified in Dhaka in May 2017 and In July 2017 the Government of Bangladesh activated its Emergency Operations Center for the first time in response to the outbreak, prompting the dissemination of prevention messages to the community. Bangladesh’s Institute of Epidemiology, Disease Control and Research (IEDCR) assigned 11 Advanced Field Epidemiology Training Program (FETP) fellows as key organizers of a one-day Chikungunya Awareness Campaign to perform Ministry of Health senior level duties. 

 

Restraints 

 

High cost of treatment and diagnosis for Chikungunya Diagnostics & Treatment

The researchers have estimated the “immediate” cost of chikungunya in India at US$ 1.48 billion (‎range US$ 0.64 billion to US$ 3.60 billion)‎. These high cost associated with the Chikungunya Diagnostics & Treatment is hampering the market growth. The largest epidemic ever recorded for chikungunya, a disease caused by infection with the chikungunya virus (CHIKV), began in Africa in 2004 and spread to >100 countries on four continents. The epidemic caused >10 million cases of often debilitating rheumatic disease, classically involving the rapid onset of fever and polyarthralgia, often with polyarthritis. The clinical diagnosis of chikungunya is often complicated by infections with dengue or Zika virus. For many individuals with chikungunya, the disease is benign and self-limiting; however, some patients have a complex spectrum of atypical and severe manifestations. Many patients also experience a chronic phase of the disease, primarily involving arthralgia (which can be protracted (>1 year)), and several sequelae are also recognized. CHIKV-induced arthropathy arises from infection of multiple cell types in the joint and the infiltration of mainly mononuclear cells.

 

Impact of COVID-19 in industry

 

The global economy and humanity have been pushed into a crisis due to the COVID-19 pandemic. Due to the high infection rate and adverse impact on public health systems, various governments have enforced nationwide lockdowns significantly impacting manufacturing supply chains, trade, and related services. Players are currently considering digital solutions that would enable them to serve the community and provide new opportunities to do business. The production, manufacturing, supply chain, and other operations, have slowed down globally aimed to limit the spread of the coronavirus. The global impact of the coronavirus disease 2019 (COVID-19) is likely only beginning and would significantly affect the Chikungunya Diagnostics & Treatment market in 2020. Though, the COVID-19 pandemic has positively impacted the market demand from enterprises in 2020. 

 

Chikungunya Diagnostics & Treatment  Market: By End User 

 

Based on the end-user, the Chikungunya Diagnostics & Treatment market is segmented into hospitals and clinics, academic institutes, research laboratories, and others. The research laboratories segment is expected to account for a major share of the market during the forecast period, due to the increasing incidence of mosquito-transmitted diseases and high investments in research laboratories. Most commonly, the mosquitoes involved are Aedes aegypti and Aedes albopictus. Out of 98 countries that reported both diseases, 13 recorded co-infections. The researchers say that due to the similarity of symptoms between dengue and chikungunya, improved and inexpensive diagnostic tests are desperately needed.

 

Source: BlueWeave Consulting

 

Chikungunya Diagnostics & Treatment Market: Regional Insight

North America region is likely to dominate in the Chikungunya Diagnostics & Treatment market, followed by the Asia Pacific, and others. The developing countries like the US and Canada have major opportunities for industrial production, retail sales, and fixed-asset investment for the Chikungunya Diagnostics & Treatment  Several other economies such as Indonesia, the Philippines, and Singapore in the Asia Pacific region are also forecast to grow at modest rates. The company's productivity is directly proportional to the productivity of workers. Hence, businesses in these regions are commonly embracing different instruments to help workers increase their productivity.

Source: BlueWeave Consulting

 

Recent Development

 

·      Altona Diagnostics recently launched and distributed the CE-IVD marked real-time PCR test kits for Zika virus detection as well as Dengue and Chikungunya (RealStar Zika Virus RT-PCR Kit 1.0, RealStar Dengue RT-PCR Kit 2.0 und RealStar Chikungunya RT-PCR Kit 2.0).

 

·    For instance, new chikungunya VLP vaccine was developed by researchers that were previously tested in a small Phase 1 trial. These results suggested that the vaccine was safe, would likely produce a potentially protective immune response to the chikungunya virus. The chikungunya vaccine candidate being tested in this trial, known as CHIKV VLP, and contains virus-like particles (VLPs), which are manufactured in mammal cells.

 

Competitive landscape

The Chikungunya Diagnostics & Treatment market is fragmented owing to the presence of numerous companies that provides varied Chikungunyafever products. However, the companies that hold the majority share of Chikungunya Diagnostics & Treatment market are Quest Diagnostics Incorporated. Alere., Genome Diagnostics Pvt. Ltd.,Altona Diagnostic, Bio-Rad Laboratories, Inc. (U.S.A), Sanat Products Ltd. Taj Pharmaceuticals Limited., and EtubicsCorporation, and other prominent players.

In the Chikungunya Diagnostics & Treatment market, prominent market participants compete on the basis of price and product quality. Small and medium-sized market players are expected to show considerable improvements in the foreseeable future, given the moderate level of capital expenditure needed to set up a business. The large-sized companies, however, are likely to aim for global expansion, in a bid to gain a more considerable brand reputation.

Scope of the Report

Attribute	Details
Years Considered	Historical data – 2017-2020 Base Year – 2020 Forecast – 2021 – 2027
Facts Covered	Revenue in USD Billion
Market Coverage	U.S, Canada, Germany, UK, France, Italy, Spain, Russia, Brazil, Japan, South Korea, China, UAE, South Africa, UAE, Turkey, India, Rest of APAC, Mexico, Argentina, Rest of Latin America, Saudi Arabia, Rest of MEA, Rest of Europe, GCC
Product/Service Segmentation	ByDiagnosis, By Treatment, By End User , By Region
Key Players	Quest Diagnostics Incorporated. Alere., Genome Diagnostics Pvt. Ltd. ,altona Diagnostics , Bio-Rad Laboratories, Inc. Sanat Products Ltd. Taj Pharmaceuticals Limited. , and Etubics Corporationand others.

 

Scope of the Report

By Diagnosis

1. ELISA Based Assay

• IgM Based Assay
• IgG Based Assay

2. Serological Tests

3. Virological Tests

4. Others

By Treatment

1. Allopathy

• Anti-pyretics
• Optimal Analgesics
• Others

2. Homoeopathy

• Pyroginum
• Rhus-Tox
• Cedron
• Others

3. Ayurveda

• Amrutharista
• MahasudarshanaChurna
• DhanvantaramGutika
• Others

By End User

1.Hospital and Clinics

2. Academic Institutes

3. Research Laboratories

4. Others

By Region

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

 

-